NASDAQ:NTRB

Nutriband Stock Insider Trading

Healthcare > Biotechnology

Buy NTRB

*Your capital is at risk

$3.51

-0.0400 (-1.13%)

At Close: Jun 03, 2026

Nutriband Stock Insider Power

Based on the 72 latest insides trades, we have calculated the insider power to be positive at 99.02. In total, the insiders bought 1.49M and sold 3.05M NTRB shares in the last 72 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 72 transactions)	99.02
● Buy	1.49M shares
● Sell	3.05M shares
82% Buy Activity Negligible or No Correlation
Buy Signal Medium Confidence Jun 01, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 99.02. Signal is based on a moderate data reliability score of 60. Supported by overwhelming buy-side pressure (82% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jul 31, 2018 Buy	Common Stock, par value $0.001 per share A-Award	Davidov Michael Director	Director	5 000 Value: $0
Jul 31, 2018 Buy	Common Stock, par value $0.001 per share A-Award	Davidov Michael Director	Director	5 000 Value: $0
May 31, 2018 Buy	Common Stock J-Other	Davidov Michael	Director	0 Value: $0
May 31, 2018 Buy	Common Stock J-Other	Davidov Michael	Director	0 Value: $0
Jan 31, 2018 Buy	Common Stock J-Other	Sheridan Gareth CEO	CEO / President	0 Value: $0
Jan 31, 2018 Buy	Common Stock, par value $0.001 per share	Melnik Serguei CFO	C-Suite Officer	0 Value: $0
Jan 31, 2018 Buy	Common Stock, par value $0.001 per share	Melnik Serguei CFO	C-Suite Officer	0 Value: $0
Jan 31, 2018 Buy	Common Stock, par value $0. 001 per share	Melnik Serguei CFO	C-Suite Officer	0 Value: $0
Jan 31, 2018 Buy	Common Stock J-Other	Sheridan Gareth CEO	CEO / President	0 Value: $0
Jan 31, 2018 Buy	Common Stock, par value $0. 001 per share	Melnik Serguei CFO	C-Suite Officer	0 Value: $0
Jan 31, 2018 Buy	Common Stock, par value $0.001 per share	Melnik Serguei CFO	C-Suite Officer	0 Value: $0
Jan 31, 2018 Buy	Common Stock, par value $0.001 per share	Melnik Serguei CFO	C-Suite Officer	0 Value: $0
Aug 19, 2017 Sell	Common Stock G-Gift	Melnik Serguei CFO	C-Suite Officer	450 000 Value: $450
Aug 19, 2017 Sell	Common Stock G-Gift	Melnik Serguei CFO	C-Suite Officer	450 000 Value: $450
Aug 17, 2017 Sell	Common Stock G-Gift	Sheridan Gareth CEO	CEO / President	1 000 000 Value: $1K
Aug 17, 2017 Sell	Common Stock G-Gift	Sheridan Gareth CEO	CEO / President	1 000 000 Value: $1K
Jan 31, 2017 Buy	Common Stock J-Other	Melnik Serguei Chief Financial Officer	C-Suite Officer	0 Value: $0
Jan 31, 2017 Buy	Common Stock J-Other	Botgros Vitalie Chairman Of The Bod	CEO / President	0 Value: $0
Jan 31, 2017 Buy	Common Stock J-Other	Sheridan Gareth CEO	CEO / President	0 Value: $0
Jan 31, 2017 Buy	Common Stock J-Other	Sheridan Gareth CEO	CEO / President	0 Value: $0
Jan 31, 2017 Buy	Common Stock J-Other	Melnik Serguei Chief Financial Officer	C-Suite Officer	0 Value: $0
Jan 31, 2017 Buy	Common Stock J-Other	Botgros Vitalie Chairman Of The Bod	CEO / President	0 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT NUTRIBAND INC.

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; e...

Read Full Profile Here